Dafni Katrana

Herbert Smith Freehills (Brussels)
Lawyer (Associate)

Dafni deals with various areas of EU competition law, including merger control (M&A and joint ventures), cartel and antitrust investigations, horizontal and vertical agreements and compliance programmes. Dafni advises clients active in a broad range of industries including pharmaceuticals, consumer goods, financial services and energy. Dafni has particular expertise in the pharmaceutical sector, where she advises major international companies on patent settlements and licensing agreements, life-cycle management strategies and merger control issues.

Distinctions

Linked authors

Herbert Smith Freehills (Brussels)
Herbert Smith Freehills (London)
Herbert Smith Freehills (London)
Herbert Smith Freehills (London)
Herbert Smith Freehills (Brussels)

Articles

92 Bulletin

Kyriakos Fountoukakos, Dafni Katrana, Ruth Allen The EU Court of Justice clarifies the criteria for the "pay-for-delay" agreements in the pharmaceutical sector (Generics - UK)

79

On 30 January 2020 the European Court of Justice (“ECJ”) clarified for the first time the criteria governing whether so-called “pay-for-delay” agreements entered into between originator and generic pharmaceutical companies fall foul of EU competition law rules. Such agreements are a form of patent (...)

Sebastien Moore, Kyriakos Fountoukakos, Mark Jephcott, Dafni Katrana, Peter Rowland The EU General Court hands down a judgement concerning an appeal brought by an undertaking and a number of generic companies against a EU Commission decision which found that the parties had breached Article 101 TFEU by agreeing to delay the market entry of a generic drug (Lundbeck)

13

On 8 September 2016 the General Court (GC) handed down its judgments in relation to the appeals brought by Lundbeck and a number of generic companies (Sun Pharma (Ranbaxy), Arrow, Generics UK, Merck and Xellia/Alpharma) against a European Commission (Commission) decision finding that the (...)

Send a message